1230 QT Reg
BioCentury & Getty Images


Dec. 30 Quick Takes: A first for Chi-Med; plus Orphazyme, BMS, FDA REMS, Pfizer, Astellas, Alkermes, Osmotica, Quanterix, Ampio and Novartis

Dec 31, 2020 | 3:18 AM GMT

Chi-Med’s surufatinib approved in China
China’s National Medical Products Administration (NMPA) approved an NDA from Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) for Sulanda surufatinib to treat non-pancreatic

Read the full 645 word article

How to gain access

Continue reading with a
two-week free trial.